期刊
JOURNAL OF CELLULAR BIOCHEMISTRY
卷 119, 期 1, 页码 748-757出版社
WILEY
DOI: 10.1002/jcb.26238
关键词
osteoblast differentiation; osterix; pseudoshikonin I; Runx2
资金
- Technology Commercialization Support Program
- Ministry of Agriculture, Food and Rural Affairs (MAFRA) [816009-2]
- Next Generation Bio-Green 21 Project
- Rural Development Administration
- Republic of Korea [PJ01122301]
Pseudoshikonin I (PSI), a novel biomaterial isolated from Lithospermi radix, has been recognized as an herbal medicine for the treatment of infectious and inflammatory diseases. Bone remodeling maintains a balance through bone resorption (osteoclastogenesis) and bone formation (osteoblastogenesis). Bone formation is generally attributed to osteoblasts. However, the effects of PSI on the bone are not well known. In this study, we found that the ethanol extracts of PSI induced osteoblast differentiation by increasing the expression of bone morphogenic protein 4 (BMP 4). PSI positively regulates the transcriptional expression and osteogenic activity of osteoblast-specific transcription factors such as Runx2 and Osterix. To identify the signaling pathways that mediate PSI-induced osteoblastogenesis, we examined the effects of serine-threonine kinase inhibitors that are known regulators of Osterix and Runx2. PSI-induced upregulation of Osterix and Runx2 was suppressed by treatment with AKT and PKA inhibitors. These results suggest that PSI enhances osteoblast differentiation by stimulating Osterix and Runx2 via the AKT and PKA signaling pathways. Thus, the activation of Runx2 and Osterix is modulated by PSI, thereby demonstrating its potential as a treatment target for bone disease. PSI enhances osteoblast differentiation by influencing transcript and protein levels of the osteoblast transcription factors Osterix and Runx2. PSI regulates Runx2 and Osterix expression through PKA and AKT signaling in osteoblast differentiation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据